The safety alert includes tests intended to detect pregnancy.
All articles by Diana Ernst, RPh
Wegovy is a glucagon-like peptide-1 receptor agonist.
Increased demand for the drug has resulted in supply interruptions.
A decision on the OTC oral contraceptive pill is expected later this year.
TransCon PTH is an investigational, once-daily, long-acting prodrug of parathyroid hormone.
The first shipments of the MiniMed 780G system are expected this summer with preorders beginning on May 15, 2023.
Both products were discontinued because of a business decision and not due to safety or efficacy-related concerns.
The prescription-only device works with integrated continuous glucose monitors and alternate controller enabled pumps.
The Company is now working with insulin pump manufacturers to integrate their AID systems with the FreeStyle Libre 2 and FreeStyle Libre 3 sensors.
It was originally approved in 2019 for the treatment of chronic pain.
Results showed that treatment with abaloparatide for 12 months resulted in significant increases in bone mineral density compared with placebo.
Semaglutide is a glucagon-like peptide-1 receptor agonist.
The recommendations were give a “D” grade indicating that there is moderate or high certainty that the harms associated with hormone therapy use in these settings outweigh any potential benefits.
Treatment with tirzepatide was associated with significant weight loss in obese and overweight adults in the SURMOUNT-1 trial.
The study authors conducted a nationwide cohort study that included 137,667 Medicare beneficiaries.
The long-acting human insulin analogue has an identical amino acid sequence to Lantus® (insulin glargine; Sanofi).
The FDA has approved the FreeStyle® Libre 2 integrated continuous glucose monitoring system (Abbott) for adults and children ≥4 years of age with diabetes.
The FDA has approved Trulicity (dulaglutide; Lilly) to reduce the risk of major adverse cardiovascular events (MACE; cardiovascular death, nonfatal myocardial infarction [MI], or nonfatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.
Novo Nordisk announced the launch of several new programs that are intended to improve insulin affordability for US patients. These programs include: My$99Insulin: Patients will be allowed to purchase up to 3 vials or 2 packs of FlexPen/FlexTouch/PenFill pens of any combination of Novo Nordisk insulins (ie, NovoLog, Novolog Mix 70/30, Levemir, Tresiba, Fiasp, Novolin…
The FDA is investigating metformin products in the US based on these reports; currently no metformin products have been recalled.
Results showed that those with private insurance were more likely than those with Medicaid to request a lower-cost alternative.